May 19, 2026 by Alex Coxon

The closure of the latest UK REACH consultation marks another important step in the evolution of the post-Brexit chemicals regime, but for many businesses, the significance is less about the consultation itself and more about what it signals operationally.

After several years of uncertainty, the direction of travel around UK REACH is becoming clearer, and alignment with EU REACH is being given greater weight in decision-making.

Much of the discussion continues to centre around the proposed Alternative Transitional Registration model (ATRm), which was developed in response to industry concerns over the cost and complexity of duplicating EU REACH registrations within Great Britain. Earlier government estimates suggested full replication of EU datasets under UK REACH could cost the industry approximately £2 billion by 2030.

The evolving ATRm approach increasingly suggests that the UK government has recognised a practical reality that industry has highlighted for several years: reproducing EU REACH in full and even increasing the data requirements in some areas was always likely to introduce substantial duplication and barriers to market without necessarily delivering proportionate regulatory value.

Critically, the UK government's response to the consultation sends a clear signal that additional registration requirements that exceed those currently required under UK and EU REACH will not be introduced as previously proposed. Instead, the UK approach appears to be moving toward a more targeted model focused on hazard conclusions, modified chemical safety assessments and regulator access to underlying data where required.

In practice, this represents an important shift.

Early discussions around UK REACH often focused on creating a fully independent regulatory framework. The current direction increasingly looks more pragmatic: preserving regulatory sovereignty while recognising the operational realities of integrated EU and GB supply chains.

That distinction matters because the central question for many businesses is evolving.

The debate is no longer simply whether UK REACH diverges from EU REACH. The more commercially important question is whether the inevitable divergence creates regulatory value proportionate to the cost and complexity it introduces into the market.

That does not mean UK REACH is becoming a lighter touch.

The Health and Safety Executive will continue to retain powers to request additional information and evaluate registrations where concerns arise. Where concerns are substantiated, the proposed amendments to UK REACH are intended to allow the HSE to be more responsive and take impactful action more quickly, such as through the introduction of Restrictions. Therefore, organisations will still need robust substance understanding, defensible hazard positions, and sufficient visibility across their supply chains to respond credibly to regulatory scrutiny.

The proposed extension of registration deadlines to as late as October 2031 under the preferred government option also reinforces that the system is still transitioning toward its long-term implementation model.

The consultation closure, therefore, feels less like an endpoint and more like the beginning of a more operational phase of UK REACH. The policy direction is becoming clearer. The implementation challenge now begins in earnest.

If you would like to discuss how the evolving UK REACH framework may affect your organisation, substances, or GB supply chains, please feel free to contact Yordas.

The ATRm is the UK Government’s proposed alternative to requiring full duplication of EU REACH registration datasets within Great Britain. The model is intended to reduce unnecessary cost and administrative burden while still allowing the regulator access to relevant hazard and use information where required.
No. While ATRm may reduce the amount of data duplication required, businesses will still need to understand their substances, uses, supply chains, and regulatory responsibilities. The Health and Safety Executive retains powers to request additional information where necessary.
The consultation proposed extending current submission deadlines, potentially as far as October 2031 under the preferred government option. The intention is to provide additional time for implementation of the ATRm framework and for businesses to prepare accordingly.
Organisations should increasingly be reviewing:
- substance portfolios placed on the GB market,
- supply-chain dependencies,
- access to hazard and use information,
- existing Only Representative arrangements,
- and the potential long-term impact of UK-specific regulatory obligations on commercial operations.